Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients".
